NCT03342144Recruiting
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
Summary
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.
Inclusion criteria
\- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment.
Exclusion criteria
\- None
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland, Germany, Austria
- Sponsor
- AbbVie(Industry)
- Protocol no.
- P17-132
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- —
Locations · 5
- Neuchâtel, SwitzerlandRéseau Hospitalier Neuchâtelois /ID# 227865Recruiting at this site
- Deggendorf, GermanyDonauisar Klinikum Deggendorf /ID# 289012Recruiting at this site
- Frankfurt am Main, GermanyVarisano Klinikum Frankfurt Hoechst /ID# 288028Recruiting at this site
- Hanau, GermanyOnkologische Schwerpunktpraxis Hanau /ID# 287948Recruiting at this site
- Magdeburg, GermanyGemeinschaftspraxis fuer Haematologie und Onkologie /ID# 281328Recruiting at this site
In total, worldwide, 5 of the 74 sites listed in the registry are recruiting; the other 69 are not currently recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: October 21, 2026).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.